A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas (NCT04104776)

🧪 Interventions in This Study

• Tulmimetostat (DRUG)
• Enzalutamide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (80 Sites)

Showing the first 25 of 80 sites.

• H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida
• Winship Cancer Institute of Emory University — Atlanta, Georgia
• University of Chicago Medical Center — Chicago, Illinois
• Loyola University Medical Center — Maywood, Illinois
• University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• Dana Farber Cancer Institute — Boston, Massachusetts
• University of Michigan Hospitals — Ann Arbor, Michigan
• South Texas Accelerated Research Therapeutics (START) - Midwest Location — Grand Rapids, Michigan
• Hackensack University Medical Center — Hackensack, New Jersey
• Roswell Park Cancer Institute — Buffalo, New York
• Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
• Memorial Sloan Kettering Cancer Center - NYC — New York, New York
• Weill Medical College of Cornell University — New York, New York
• University of Rochester Medical Center, James P. Wilmot Cancer Center — Rochester, New York
• Montefiore Medical Center, Montefiore Medical Center Laboratories — The Bronx, New York
• University of Cincinnati Medical Center — Cincinnati, Ohio
• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania
• South Texas Accelerated Research Therapeutics — San Antonio, Texas
• University of Virginia Health System — Charlottesville, Virginia
• Swedish Cancer Institute — Seattle, Washington
• Fred Hutchinson Cancer Center — Seattle, Washington
• CHU Bordeaux Hopital Saint Andre — Bordeaux,
• CLCC Institut Bergonie — Bordeaux,
• Centre Oscar Lambret — Lille,

📞 Contact the Study Coordinator

Phone: (888) 669-6682

Email: novartis.email@novartis.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumor

• Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
• A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
• QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
• A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
• First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
• A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas

Explore by condition: All Advanced Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.